Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab with Chemoradiotherapy for Nasopharyngeal Cancer
NCT00408694Phase 2
Key facts
- Status
- Completed
- Start
- Dec 2006
- Primary completion
- Dec 2011
- Countries
- 2
- Sponsor
- National Cancer Institute
- Modality
- Monoclonal Antibodies
- Drugs
- bevacizumab
- Conditions
- nasopharyngeal carcinoma (NPC)
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in nasopharyngeal carcinoma (NPC), sponsored by National Cancer Institute. Primary endpoint: Percentage of Patients With a Grade 4 Hemorrhage or Any Grade 5 Adverse Event Assessed to be Definitely, Probably, or Possibly Related to Protocol Treatment During the First Year at 1 year. Started Dec 2006; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
Treatment
Bevacizumab + Chemoradiotherapy followed by Adjuvant Bevacizumab + Chemo
03
Endpoints
Primary
Percentage of Patients With a Grade 4 Hemorrhage or Any Grade 5 Adverse Event Assessed to be Definitely, Probably, or Possibly Related to Protocol Treatment During the First Year
Secondary
One- and Two-year Loco-regional Progression-free Rates
One- and Two-year Distant Metastases-free Rates
One- and Two-year Progression-free Survival Rates
One- and Two-year Overall Survival Rates
Beyond the preview
Go deeper on NCT00408694.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00408694.